anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a method for preparing anti-cancer total saponin extractsof oplopanax elatus nakai leaves and application thereof in anti-cancer medicaments. The method comprises the following steps: 1) crashing the oplopanax elatus nakai leaves into coarse powder; 2) extracting the powder of the oplopanax elatus nakai leaves by using water or aqueous ethanol; filtering the obtained extracting solution, combining filtrates and concentrating the filtrates to obtain a concentrated liquor; and 3) concentrating the concentrated liquor at a reduced pressure and drying the concentrate to obtain the total saponin extracts of oplopanax elatus nakai leaves. The total saponins in the total saponin extracts of the oplopanax elatus nakai leaves prepared by the method accounts for over 20 percent of the weight of the total saponin extracts of the oplopanax elatus nakai leaves and the yield is of between 1 to 30 percent. Pharmacological tests prove that the extracts have a good anti-caner effect. The total saponin extracts of the oplopanax elatus nakai leaves can be applied alone or in combination with other medicaments to serve as a raw material medicament for preparing a medicament preparation with the anti-cancer effect. The product prepared by the method is high in purity and the method is simple and practical and suitable for industrial production.
We combined single nuclei RNA sequencing with spatial transcriptomics and single-cell resolution spatial proteomic analysis of human bladder cancer to identify an epithelial subpopulation with therapeutic response prediction ability. These cells express Cadherin 12 (CDH12, N-Cadherin 2), catenins, and other epithelial markers. CDH12-enriched tumors define patients with poor outcome following surgery with or without neoadjuvant chemotherapy (NAC), whereas CDH12-enriched tumors have a superior response to immune checkpoint therapy (ICT). Patient stratification by tumor CDH12 enrichment offered better prediction outcome than established bladder cancer subtypes. The CDH12 population resembles an undifferentiated state with chemoresistance. CDH12-enriched cells express PD-L1 and PD-L2 and co-localize with exhausted T-cells, possibly mediated through CD49a (ITGA1), likely explaining ICT efficacy in these tumors. This invention identifies a cancer cell population with a diametric response to major bladder cancer therapeutics, and provides a framework for designing biomarker-guided clinical trials.
PCT No. PCT/DK94/00072 Sec. 371 Date Aug. 30, 1995 Sec. 102(e) Date Aug. 30, 1995 PCT Filed Feb. 21, 1994 PCT Pub. No. WO94/19411 PCT Pub. Date Sep. 1, 1994A powdered water-dispersible carotenoid preparation in the form of discrete carotenoid microparticles is prepared by milling a carotenoid in an aqueous medium in the presence of a hydrocolloid so as to form a suspension, heating the suspension thus formed to a sufficiently high temperature to cause a total or partial melting of the carotenoid and cooling, finely dividing and drying the suspension to form a powder.
Recent studies indicate that veterans who engage in suicidal behavior have a history of traumatic brain injury (TBI), and veterans with a history of TBI engage in suicidal behavior. Existing research also suggests an association between suicidality and executive dysfunction (e.g., impaired decision making). To date a clearly defined study has not been conducted to explore the relationship between executive dysfunction as a multidimensional construct (i.e., decision making, impulsivity, concept formation, and aggression) and suicidal behavior in the vulnerable population of those with a history of moderate to severe TBI. Increased understanding regarding this at-risk population is necessary to facilitate the creation of appropriate assessment strategies and interventions. This study will assess decision making in the context of an interaction between suicide and TBI. Findings will also allow for exploratory analyses aimed at identifying associations between performance on measures of executive functioning and psychological distress. Toward this end, the present study seeks to compare test performance among four well-defined groups of veterans: (1) those with moderate to severe TBI and a history of suicidal behavior; (2) those with moderate to severe TBI and no history of suicidal behavior; (3) those with no TBI and a history of suicidal behavior; (4) and those with no TBI and no history of suicidal behavior. This grant proposal is in direct support of the Rehabilitation Research and Development goal of maximizing functional recovery in those with TBI by potentially: 1) increasing clinicians' ability to identify neuropsychological correlates of suicidal behavior for those with moderate to severe TBI; 2) identifying psychometrically sound measures of executive functioning that correspond to real-life behaviors that impact treatment response and recovery; 3) facilitating the creation of innovative assessment techniques and psychosocial interventions (e.g., safety planning) to minimize complications in the management of suicidal behavior due to TBI-related impairments; and 4) creating a basis for further and much-needed research in this area. Ultimately, findings from this study would both contribute to clinicians' ability to identify veterans with TBI who are at risk for suicidal behavior, and create a foundation on which to base further research regarding the relationships between cognition, emotional distress, and suicidality in TBI survivors.
Alcohol use disorder (AUD) is a heterogeneous and chronic relapsing disorder that includes both acute (binge drinking) and chronic (frequent heavy drinking) dimensions. Perhaps because of this heterogeneity, the therapeutic effect size of the approved medicines for the treatment of AUD has been small. In an effort to overcome the heterogeneity of response to a particular medication, recent studies have instituted a personalized approach to therapy. Major breakthroughs in pharmacogenetics have made it possible to identify discrete subgroups of the AUD population according to genetic profiles in order to target the subjects who are most likely to respond to treatment with a particular agent. In addition, genetic variation contributing to the risk of alcohol dependence may be differentially associated with treatment response Thus a successful personalized medicinal approach should ensure that targeted subgroups achieve an optimal treatment response with high predictability. Such an approach holds the potential to identify not only robust responders to treatment but also those who might have minimal or modest adverse effects from the putative therapeutic medication. From a practical clinical standpoint, a personalized medicine approach starts with a genetic screen to identify the "right" subject, who can then be treated with the appropriate medication, with a high probability of a positive treatment outcome and, therefore, a substantial impact on public health.
The aim of this study is to observe the relationship between the WPI and SS parameters in the ACR 2016 criteria for fibromyalgia, separately, with the severity of the disease, pain level, quality of life and anxiety level. Accordingly, the investigators aim to evaluate whether WPI or SS has priority in assessing the severity of the disease. There is no study in the literature comparing the importance of the 2016 ACR diagnostic parameters on the disease effect. In this context, this study will be the first study in the literature and will be very valuable. Patients visiting the outpatient clinic with FMS diagnosis will be evaluated. Patients will be asked to fill the World Health Organization Short Quality of Life Questionnaire, and the McGill Melzack Pain Questionnaire and Beck Anxiety Questionnaire . The patients will be assed by an experienced Physical Medicine and Rehabilitation specialist for SS and WPI scores.
1392131 Cultivating plankton; cosmetic product M AUBERT 13 Dec 1972 [15 Dec 1971] 57497/72 Heading A5B A product useful in preparing cosmetics is produced by (a) cultivating a marine plankton, (b) separating the cultured cells from the culture medium, (c) rupturing the cells and (d) subjecting the nucleoplasma to a preservation process. The plankton may be Asterionella Japonica or Chaetoceros teres. The cells may be separated from the culture medium by filtration, centrifuging or dialysis. The nucleoplasma may be freed of thecae and mineral substances. The preservation process may comprise lyophilisation or addition of a preservative. A skin cream may contain lanolin, glycerine, water and the product of the invention.
20 patients with (13 with ET and 7 with PD) with at least mild postural tremor were enrolled in a prospective, single-center, two-arm, crossover study that took place over the course of four weeks. TAPS devices were shipped to patients to run the study remotely. In the first arm of the study, subjects received TAPS treatment using the original. Cala Trio band for two weeks. Followed by a wash-out period (\> 24 hours), subjects entered the second arm and received TAPS using the Trio+ band for an additional two weeks. Unsupervised motion assessments were captured at home, and at the beginning and end of the four weeks by telemedicine.
Background: In Brazil, community health workers (CHW) are members of the community hired by the government to provide education and care for patients for a broad range of health issues, including diabetes mellitus (DM). However, few CHW are trained for diabetes education and little is known about the effectiveness of their interventions. The aim of this study is to evaluate the effect of a diabetes education program delivered to CHW in improving the metabolic control of patients with type 2 DM.

Materials and methods: the study is a randomized controlled trial conducted in a primary care unit. Eight CHW, providing care for 118 patients, are randomized in two groups to receive a one-month diabetes education program (intervention group, patients n= 62) or an education course in other health issues (control group, patients n= 56). Each CHW is responsible for transmitting the acquired knowledge to patients from their respective working areas. The primary outcome is change in HbA1C three months after intervention.
Hemodialysis nurses received educational program about antimicrobial resistance and uses in hemodialysis units. The program developed by the researcher is meticulously designed, drawing on extensive insights from the WHO curricula guide (nurses' education and training on antimicrobial resistance; 2019) and the literature review addressed the use of antibiotics and prevention of AMR in hemodialysis facilities.
Identification of patients who are at highest risk for heart attack is an important task for emergency medicine physicians. Currently, physicians use a variety of different scoring systems to stratify their risk for having a heart attack. Heart rate variability (HRV) is a measure derived from noninvasive cardiac monitoring. This data is collected from a simple, non-invasive chest strap during a 10-minute recording session. The purpose of this proposal is to collect heart rate variability data on patients admitted to the emergency department with chest pain. The intent is to measure the association between heart rate variability and the various risk stratification scoring systems for chest pain.

The investigators propose to enroll patients admitted to the emergency department with chest pain. In addition to HRV data, clinical risk factors will be obtained, using validated clinical risk scoring systems. The team will follow patient's clinical course in order to include information about the determined cause of chest pain. The goal is to understand how HRV can augment common risk stratification scoring systems for patient presenting to the ED with chest pain.
PURPOSE:To obtain a therapeutic agent capable of shortening residence time of digestive tract of food and improving evacuation and useful for prevention and treatment of chronic constipation by containing a hydrolyzate of guar gum as an active ingredient. CONSTITUTION:The preventing and treating agent containing a hydrolyzate of guar gum obtained by hydrolyzing guar gum using an enzyme, e.g. an enzyme produced by alkalophilic Bacillus bacterium, preferably hydrolyzate of quar gum having 4000-50000 average molecular weight and composition ratio of mannose: galactose of (1.5-2.0): 1.0 and being 100-1000cp in viscosity at 20 deg.C in the case of 40wt.% aqueous solution as an active ingredient. The effective dose of the compound is 1-10g per day and preferably administered once per day or in divided dose. The compound has high safety and is administrable and capable of readily carrying out addition to food or processing thereof. Thereby prevention and treatment of chronic constipation is especially made possible.
Olvi-Vec (olvimulogene nanivacirepvec, aka GL-ONC1; laboratory name: GLV-1h68) is an oncolytic vaccinia virus-based immunotherapy that has been shown to have broad infectivity in a wide range of tumor types including non-small-cell lung cancer (NSCLC). In preclinical studies, Olvi-Vec was shown to infect and kill NSCLC cells and tumors in vitro and in vivo, respectively, and resolved and prevented formation of malignant effusion. This study is to test the hypothesis that the combination of Olvi-Vec followed by further platinum-based chemotherapy plus an ICI is particularly effective against established tumors by virus-mediated immune activation and re-sensitization of tumor cells to chemotherapy. Participants will have advanced or metastatic NSCLC (Stage III or Stage IV) squamous or nonsquamous disease without known targetable alterations in Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK) or Repressor of Silencing 1 (ROS1). Eligible patients will have first disease progression by radiological assessment (i) while on front-line platinum-doublet chemotherapy and ICI, or (ii) while receiving front-line maintenance ICI-based therapy after completion of front-line therapy, with at least 2 cycles and maximum of 6 cycles of platinum-doublet chemotherapy and ICI, regardless of Programmed death-ligand 1 (PD-L1) expression as the first treatment after being diagnosed. ICI includes anti-programmed death-1 (anti-PD-1) or anti-PD-L1 agents. Other classes of ICI \[e.g., anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), etc.\] are excluded. Patients will be stratified based on length of time on ICI-based therapy from start date of the first dose, if ICI during front-line therapy, until date of first progression by radiological assessment is either less than or equal to 4 months or greater than 4 months. Patients enrolled in one of the initial 3 cohorts will receive either 3 or 4 days of Olvi-Vec followed by platinum-doublet chemotherapy + Physician's Choice of ICI. The randomization part of the study will start afterwards with the Olvi-Vec dose and schedule selected from one of the 3 cohorts for the Experimental Arm. The Active Comparator Arm (ACA) treatment includes docetaxel. Participants treated in the ACA who subsequently have documented disease progression may cross-over for treatment as per the Experimental Arm following determination of eligibility.
A 2-week therapeutic ketogenic diet (TKD) induction will be implemented to establish nutritional ketosis (the goal are BHB blood levels of 0.5-3.0 millimoles per liter \[mmol/L\]). After establishing the ketotic state, study participants will continue TKD for 12 weeks.
Adult patients (≥ 18 years) with skin pathologies seen in the primary care service of health centers referring to Cruces and Basurto University Hospitals. Patients participating in this study did not receive any specific treatment as part of the research protocol. Patients continued their regular prescribed medications and treatments as directed by their primary healthcare providers. No additional medications or treatments were administered as part of this study.
The present invention relates to a medicine for regulating immunity and a production method thereof. The medicine is in the form of granules prepared from the medicinal materials isogenous medicine and appetite of 1% to 97% of Chinese wolfberry fruit, 1% to 97% of astragalus root and 1% to 97% safflower according to proportion. The production method comprises the following steps that (1) after being mixed, the medicinal materials are soaked with water and are decocted twice; (2) decoction liquids are mixed and concentrated until 1 ml of decoction liquid contains 1g of crude drug; (3) ethanol is added until alcohol content reaches 30% to 50% on standing for 8 to 12 hours; (4) the decoction liquid is centrifugated to obtain a supernatant fluid, and the ethanol is recovered until the relative density is from 1.25 to 1.40 to prepare extractum; (5) after lactose, dextrin and corrigent are added, the extractum is granulated, dried and sieved, and the medicine of the present invention is obtained. The medicine of the present invention has the effect of regulating the immunity of human bodies. The medicine can be used for adjutant therapy of chemotherapy for patients suffering from phymatosis, and is suitable for people in old ages and weakness due to chronic diseases to take. The medicine has the advantages of unique formula, reliable therapeutic effect, low cost and no toxic or side effect.
All participants were given manual therapy based on the Fascial Distortion Model in addition to conventional therapy (Rocabado's 6x6 Exercises and Patient Education). Conventional therapy was implemented as a home program for 8 weeks, while Manual Therapy was conducted for forty-five minutes once a week in a clinical setting.
Intravenous application of tranexamic acid (TXA) in posterior lumbar interbody fusion (PLIF) can effectively reduce blood loss without affecting coagulation function. However, it has not been reported whether preoperative use of anticoagulants may affect the efficacy of TXA in PLIF. The purpose of this study is to observe the effect of preoperative use of anticoagulants on coagulation indicators and blood loss after PLIF receiving intravenous unit dose TXA. A retrospective analysis was conducted on data from 53 patients with PLIF between 2020.11 and 2022.9, who received intravenous application of a unit dose of TXA (1 g/100 mL) 15 min before the skin incision after general anesthesia. Those who used anticoagulants within one week before surgery were recorded as the observation group, while those who did not use anticoagulants were recorded as the control group. The main observation indicators include surgical time, intraoperative blood loss, postoperative drainage volume, blood transfusion, and red blood cell (RBC), hemoglobin (HB), and hematocrit (HCT) measured on the 1st, 4th, 7th, and last-test postoperative days. Secondary observation indicators included postoperative incision healing, deep vein thrombosis of lower limbs, postoperative hospital stay, and activated partial thrombin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (FIB), and platelets (PLT) on the 1st and 4th days after surgery. The operation was successfully completed in both groups, the incision healed well after operation, and no lower limb deep vein thrombosis occurred. There was no significant difference in surgical time, intraoperative blood loss, postoperative drainage volume, and blood transfusion between the two groups (p > 0.05). There was no significant difference in the RBC, HB, and HCT measured on the 1st, 4th, 7th, and last-test postoperative days between the two groups (p > 0.05). There was no statistically significant difference in APTT, PT, TT, FIB and PLT between the two groups on the 1st and 4th postoperative days (p > 0.05). There was no significant difference in postoperative hospital stay between the two groups (p > 0.05). The use of anticoagulants within one week before surgery does not affect the hemostatic effect of intravenous unit dose TXA in PLIF.
FIELD: medicine. SUBSTANCE: described are unique antigenic epitops IgE (designated ige. b1 present on IgE-producing B-lymphocytes). One class of ige.b1 epitops is linked with it near FCER-site of linking on IgE. The other class of ige.b1 epitops is associated with the extracellular ε-chain domain fixing IgE on membranes of B-cells (emb/ec). Monoclonal antibodies associated with ige.b1 epitops are used for therapy of allergic conditions induced by IgE. Separate monoclonal antibodies or antibodies conjugated with cytotoxin (immonotoxins) may be used for suppressing B- cells producing IgE. Monoclonal antibodies against idiotypes ige.b1 of specific antibodies or peptides expressing epitops may be used in active immunization of allergic patients in order to attain same results as those attained by treatment with monoclonal antibodies. EFFECT: simpler and more reliable method. 2 cl, 8 dwg, 7 tbl
INTRODUCTION: Intracerebral bleeding that predominantly affects the pons, midbrain, cerebral peduncle, basal ganglia, and thalamus may occur in severe diquat poisoning. We employed magnetic resonance-susceptibility-weighted imaging to highlight the presence of microhemorrhages in a patient with diquat poisoning.Case summary: A 15-year-old female patient presented with kidney and liver damage after ingesting diquat. Three days later, she developed coma. She received seven sessions of hemoperfusion and was discharged with residual cognitive impairment and right limb muscle weakness after 66 days of hospitalization.Images: Cranial computed tomography on day 5 and magnetic resonance imaging on day 8 revealed swelling in the pons, midbrain, and thalamus without evidence of hemorrhage. However, susceptibility-weighted imaging on day 8 demonstrated multiple punctate low signals, suggesting the presence of microhemorrhages.
CONCLUSION: Susceptibility-weighted imaging is a useful technique for detecting microhemorrhages in patients with diquat-induced encephalopathy, as microhemorrhages are often not detectable on computed tomography or conventional magnetic resonance imaging.
Dementia is a chronic, progressive brain disease that may involve a number of symptoms, including memory loss and changes in personality, behavior, judgment, attention span, language and thought. The most common type of dementia is Alzheimer's disease. Over time, patients with Alzheimer's disease may lose ability to perform daily tasks related to personal care (for example bathing, dressing, eating) and may be unable to handle money or travel to familiar places. The term mild cognitive impairment (MCI) is used to describe individuals who have memory impairments suggestive of early dementia, but do not yet meet the criteria for Alzheimer's disease. Individuals with MCI are more likely to develop Alzheimer's disease than normal elderly patients. Individuals with MCI who completed 1 of 2 previous double-blind studies with galantamine may participate in this follow-up study if they have not progressed to dementia. They will receive open-label galantamine for 12 months and will be evaluated after 2, 6 and 12 months of treatment. Safety evaluations (incidence of adverse events, ECGs, physical examinations, laboratory tests) will be performed throughout the study. Effectiveness will be assessed after 12 months of treatment (by using standardized tests and rating scales (Alzheimer's Disease Assessment Scale: cognitive/MCI version \[ADAS-Cog/MCI\], Clinical Dementia Rating \[CDR\] and CDR-Sum of the Boxes \[CDR-SB\]). Health status will be assessed using the Health Survey portion of the Short-Form 36 (SF-36) and the use of health and social care resources will be assessed using a resource-use questionnaire. The enrolled individuals may participate in an optional portion of the study in which their genetic material is analyzed to see if contains something that would affect the way galantamine is used by their bodies. Galantamine 8 or 12 milligrams (mg) by mouth twice daily for 12 months. Dose will start at 4 mg twice daily and be gradually increased to final dose; 12 mg twice daily dose may be decreased to 8 mg twice daily based upon tolerability